How Codexis, Inc.’s ECO Synthesis platform could reshape industrial RNA production workflows
Explore why Codexis, Inc.’s latest RNA manufacturing advances could influence scalability, stereochemical control, and future siRNA production economics.
How the PharmAla Biotech Holdings Inc. and Jupiter Neurosciences, Inc. deal reflects changing investor expectations in psychedelics
Explore why the PharmAla and Jupiter Neurosciences licensing deal could reshape investor sentiment around next-generation psychedelic therapeutics.
Why UroGen Pharma Ltd. sees UGN-103 as more than a follow-on bladder cancer therapy
UroGen Pharma Ltd.’s UGN-103 posted strong Phase 3 bladder cancer durability data. Find out what this means for NMIBC treatment and regulation.
How Tenaya Therapeutics, Inc. is positioning TN-401 against the limitations of current ARVC care
Could TN-401 change ARVC treatment strategy? Explore what Tenaya Therapeutics, Inc.’s RIDGE-1 data means for cardiac gene therapy.
Can Oryzon Genomics, S.A. turn iadademstat into a platform therapy for acute myeloid leukemia?
Can Oryzon Genomics turn iadademstat into a scalable AML platform therapy? Explore the EHA 2026 clinical and commercial implications.
Why Sapu Nano’s Deciparticle platform could become a broader oncology drug-delivery play
Discover how Sapu Nano’s Deciparticle platform could reshape oncology drug delivery and expand intravenous everolimus development.
How PharmAla Biotech Holdings Inc. is positioning APA-01 around traumatic brain injury and neurorehabilitation
How is PharmAla Biotech Holdings Inc. positioning APA-01 for traumatic brain injury and neurorehabilitation markets? Read the full PDN analysis.
What Can-Fite BioPharma Ltd.’s Phase 2b pancreatic cancer strategy reveals about immunotherapy combination economics
Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.
What Actuate Therapeutics, Inc.’s oral formulation push means for pancreatic cancer drug development economics
Actuate Therapeutics, Inc. is advancing oral elraglusib after FDA IND clearance. Discover what this means for pancreatic cancer economics.
How Envoy Medical, Inc.’s FDA pathway could influence the future of implantable hearing systems
Could fully implanted cochlear implants transform hearing restoration? Explore the regulatory, clinical, and market implications now.